These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 38444317)

  • 1. Efficacy of Semaglutide in Overweight and Obese Patients with Type 1 Diabetes.
    Garg SK; Kaur G; Haider Z; Rodriquez E; Beatson C; Snell-Bergeon J
    Diabetes Technol Ther; 2024 Mar; 26(3):184-189. PubMed ID: 38444317
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy and Safety of Tirzepatide in Overweight and Obese Adult Patients with Type 1 Diabetes.
    Garg SK; Akturk HK; Kaur G; Beatson C; Snell-Bergeon J
    Diabetes Technol Ther; 2024 Jun; 26(6):367-374. PubMed ID: 38512447
    [No Abstract]   [Full Text] [Related]  

  • 3. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial.
    Heise T; Mari A; DeVries JH; Urva S; Li J; Pratt EJ; Coskun T; Thomas MK; Mather KJ; Haupt A; Milicevic Z
    Lancet Diabetes Endocrinol; 2022 Jun; 10(6):418-429. PubMed ID: 35468322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.
    Davies M; Færch L; Jeppesen OK; Pakseresht A; Pedersen SD; Perreault L; Rosenstock J; Shimomura I; Viljoen A; Wadden TA; Lingvay I;
    Lancet; 2021 Mar; 397(10278):971-984. PubMed ID: 33667417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycaemia in low-premixed insulin analogue type 2 diabetes patients in a real-world setting: are the CGM targets met?
    Krajnc M; Kravos Tramšek NA
    Eur J Med Res; 2023 Mar; 28(1):111. PubMed ID: 36882852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Effects of Adding Semaglutide to High Daily Dose Insulin Regimens in Patients With Type 2 Diabetes.
    Meyer J; Dreischmeier E; Lehmann M; Phelan J
    Ann Pharmacother; 2023 Mar; 57(3):241-250. PubMed ID: 35778801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation and comparison of efficacy and safety of tirzepatide and semaglutide in patients with type 2 diabetes mellitus: A Bayesian network meta-analysis.
    Ding Y; Shi Y; Guan R; Yan S; Liu H; Wang Z; Li J; Wang T; Cai W; Ma G
    Pharmacol Res; 2024 Jan; 199():107031. PubMed ID: 38061595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial.
    Davies M; Pieber TR; Hartoft-Nielsen ML; Hansen OKH; Jabbour S; Rosenstock J
    JAMA; 2017 Oct; 318(15):1460-1470. PubMed ID: 29049653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of oral semaglutide on glucose control and body weight up to 18 months: a multicenter retrospective real-world study.
    Bonora BM; Russo G; Leonetti F; Strazzabosco M; Nollino L; Aimaretti G; Giaccari A; Broglio F; Consoli A; Avogaro A; Fadini GP;
    J Endocrinol Invest; 2024 Jun; 47(6):1395-1403. PubMed ID: 38369592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of obesity on blood glucose control using continuous glucose monitoring data among patients with type 1 diabetes.
    Nicolau J; Romano A; Rodríguez I; Sanchís P; Puga M; Masmiquel L
    Endocrinol Diabetes Nutr (Engl Ed); 2024 May; 71(5):202-207. PubMed ID: 38897703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art.
    Nauck MA; Quast DR; Wefers J; Meier JJ
    Mol Metab; 2021 Apr; 46():101102. PubMed ID: 33068776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial.
    Rodbard HW; Lingvay I; Reed J; de la Rosa R; Rose L; Sugimoto D; Araki E; Chu PL; Wijayasinghe N; Norwood P
    J Clin Endocrinol Metab; 2018 Jun; 103(6):2291-2301. PubMed ID: 29688502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparing the effectiveness of continuous subcutaneous insulin infusion with multiple daily insulin injection for patients with type 1 diabetes mellitus evaluated by retrospective continuous glucose monitoring: A real-world data analysis.
    Keyu G; Jiaqi L; Liyin Z; Jianan Y; Li F; Zhiyi D; Qin Z; Xia L; Lin Y; Zhiguang Z
    Front Public Health; 2022; 10():990281. PubMed ID: 36091534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world use of once-weekly semaglutide in patients with type 2 diabetes: pooled analysis of data from four SURE studies by baseline characteristic subgroups.
    Yale JF; Bodholdt U; Catarig AM; Catrina S; Clark A; Ekberg NR; Erhan U; Holmes P; Knudsen ST; Liutkus J; Sathyapalan T; Schultes B; Rudofsky G
    BMJ Open Diabetes Res Care; 2022 Apr; 10(2):. PubMed ID: 35383100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes.
    Tan X; Cao X; Zhou M; Zou P; Hu J
    Expert Opin Investig Drugs; 2017 Sep; 26(9):1083-1089. PubMed ID: 28741970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Randomized, Double-Blind, Placebo-Controlled Trial of Adjunctive Metformin Therapy in Overweight/Obese Youth with Type 1 Diabetes.
    Nwosu BU; Maranda L; Cullen K; Greenman L; Fleshman J; McShea N; Barton BA; Lee MM
    PLoS One; 2015; 10(9):e0137525. PubMed ID: 26367281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial.
    Pratley R; Amod A; Hoff ST; Kadowaki T; Lingvay I; Nauck M; Pedersen KB; Saugstrup T; Meier JJ;
    Lancet; 2019 Jul; 394(10192):39-50. PubMed ID: 31186120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial.
    Sorli C; Harashima SI; Tsoukas GM; Unger J; Karsbøl JD; Hansen T; Bain SC
    Lancet Diabetes Endocrinol; 2017 Apr; 5(4):251-260. PubMed ID: 28110911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in body weight and composition, metabolic parameters, and quality of life in patients with type 2 diabetes treated with subcutaneous semaglutide in real-world clinical practice.
    Pantanetti P; Cangelosi G; Alberti S; Di Marco S; Michetti G; Cerasoli G; Di Giacinti M; Coacci S; Francucci N; Petrelli F; Ambrosio G; Grinta R
    Front Endocrinol (Lausanne); 2024; 15():1394506. PubMed ID: 39015186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
    Frías JP; Davies MJ; Rosenstock J; Pérez Manghi FC; Fernández Landó L; Bergman BK; Liu B; Cui X; Brown K;
    N Engl J Med; 2021 Aug; 385(6):503-515. PubMed ID: 34170647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.